Preclinical News and Research

RSS

Non-profit public-private partnership develops affordable, new drug regimens for tuberculosis

The Global Alliance for TB Drug Development (TB Alliance), a non-profit public-private partnership developing affordable, new drug regimens for tuberculosis, today announced the start of Phase I clinical trials for the lead TB drug in its pipeline, PA-824. The trials begin this month.

14 Jun 2005

Ruboxistaurin shows favorable effects on kidney damage and function in people with type 2 diabetes and nephropathy

Eli Lilly and Company today announced encouraging results from a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with type 2 diabetes and kidney disease (also known as "diabetic nephropathy").

12 Jun 2005

Venom of marine cone snails may provide an improved treatment for neuropathic pain associated with diabetes

A cone snail toxin discovered by Melbourne researchers has proven to have great potential for easing pain and could provide an improved treatment for neuropathic pain associated with diabetes.

12 Jun 2005

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.

9 Jun 2005

Biota makes major antiviral discovery

Biota Holdings Limited announced today that it has discovered a new class of orally-effective, potent antivirals against RSV (respiratory syncytial virus) infection.

7 Jun 2005

Genetically engineered virus has shown promise as a treatment for patients with colorectal cancer

A single injection of a genetically engineered virus has shown promise as a treatment for patients with colorectal cancer that has spread to the liver, according to preliminary results reported at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.

6 Jun 2005

Triple approach is promising against cancer cells

A trimodal treatment strategy combining chemotherapy, radiation therapy, and a protein kinase inhibitor is much more effective against cancer cells than any combination of only two treatment methods.

1 Jun 2005

New approach to inhibiting blood vessel growth or angiogenesis

A manmade protein with a tail of amino acids delivered to target cells can dramatically reduce blood vessel growth that obstructs vision or feeds a tumor, researchers have found.

31 May 2005

Targepeutics issued new U.S patent

Targepeutics has announced the issuance of U.S. Patent No. 6,884,603 for its genetically modified, mutated Interleukin 13 (IL-13) technology platform for the treatment of malignant glioma, a brain tumor (17,500 people annually; $200 million annual market).

31 May 2005

Researchers generate patient-specific stem cells

Researchers have isolated the first human embryonic stem cell lines specifically tailored to match the nuclear DNA of patients, both males and females of various ages, suffering from disease or spinal cord injury.

20 May 2005

Older adults with insomnia report falling asleep faster with Ramelteon

Results from a Phase 3 clinical study presented at the 2005 Annual Scientific Meeting of the American Geriatrics Society showed that bedtime administration of ramelteon, an investigational compound currently under review for the treatment of insomnia, significantly reduced time to fall asleep in older adults with chronic insomnia. Additionally, no rebound insomnia or withdrawal effects were observed.

18 May 2005

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Peregrine Pharmaceuticals, Inc., today announced that a research article titled "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice" was published in the May 15 issue of Cancer Research.

16 May 2005

Targeted Genetics announces new patent for Hyperlipidemia

Targeted Genetics Corporation announced today issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism."

11 May 2005

Generex begins testing new vaccine for breast cancer patients

Generex Biotechnology Corporation announced today that the first patients had received a novel therapeutic vaccine developed by its wholly owned subsidiary, Antigen Express as part of the Company's Phase I Trial. The Trial will include between 16 and 24 patients.

28 Apr 2005

Australian clinical trial of potent new anticancer drug (CYT997)

Up to 30 patients with advanced incurable solid-tumours are to be involved in clinical trials of a potent new anticancer drug (CYT997), developed by Australian biotechnology company, Cytopia Limited.

27 Apr 2005

National study to evaluate the effectiveness Targacept

Wake Forest University School of Medicine is one of 15 centers nationwide recruiting participants for a research study to evaluate the effectiveness of an investigational drug as an oral treatment for age associated memory impairment (AAMI), a condition that is marked by memory loss and poor concentration.

27 Apr 2005

Guidelines for research involving human embryonic stem cells

The National Academies today recommended guidelines for research involving human embryonic stem cells, and urged all institutions conducting such research to establish oversight committees to ensure that the new guidelines will be followed.

26 Apr 2005

Australian researchers develop West Nile virus treatment

A University of Queensland researcher has developed the world's first specific immunotherapy product using monoclonal antibodies for the potentially lethal West Nile virus, which causes seasonal epidemics around the globe.

26 Apr 2005

Use of positron emission tomography may eliminate more strenuous drug development trials with animals

A number of articles explore the use of positron emission tomography (PET) and small animal imaging—nonsurgical techniques that open the door to understanding and treating human diseases—in the April issue of the Society of Nuclear Medicine’s Journal of Nuclear Medicine.

26 Apr 2005

Maxim Pharmaceuticals issued patent for method of identifying therapeutically effective immunosupressive agents

Maxim Pharmaceuticals have announced the United States Patent and Trademark Office issued U.S. patent number 6,828,091 B2, entitled "Method of Identifying Immunosuppressive Agents."

23 Apr 2005